Impax Labs (IPXL) trading halted with news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Canaccord Genuity Downgrades Impax Laboratories (IPXL) to Hold
March 5, 2013 7:03 AM ESTCanaccord Genuity downgraded Impax Laboratories (NASDAQ: IPXL) from Buy to Hold with a price target of $20.00 (from $25.00).
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings... More
Impax Labs (IPXL) to Resume Trading at 4:40pm ET
March 4, 2013 4:22 PM ESTImpax Laboratories, Inc. (Nasdaq: IPXL) to resume trading at 4:40pm EST.... More
Impax Labs (IPXL) Receives New Form 483 for Hayward Facility
March 4, 2013 4:15 PM ESTImpax Laboratories, Inc. (NASDAQ: IPXL) announced that the U.S. Food and Drug Administration (FDA) completed its re-inspection of the Companys Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012. In addition to the re-inspection, the FDA conducted a Pre-Approval Inspection (PAI) for RYTARYTM, as analytical method validation and a portion of the stability data were generated in Hayward, and a general Good Manufacturing Practices (GMP) inspection. At the conclusion of this... More
